Daria A. Teplyuk

Daria A. Teplyuk

Auto-generated profile, based on publicly available information

Daria A. Teplyuk

Botkin Hospital

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
CPChavdar Pavlov
Chavdar Pavlov
VKV. I. Kovalevskaya
V. I. Kovalevskaya
DVD. I. Varganova
D. I. Varganova
TTT. A. Turankova
T. A. Turankova
MSM. Ch. Semenistaya
M. Ch. Semenistaya
Beatrice VolelBeatrice Volel
Beatrice Volel
Technological advances in the modern world have led to a paradigm shift in medical education, identifying new challenges. The need to meet these challenges has required the implementation of evidence-based clinical practice, which allows the best quality evidence to be used to provide optimal patient care and improve healthcare efficiency. Obtaining evidence of the efficacy and safety of drugs and medical technologies, the diagnostic accuracy of interventions became possible due to the introduction of systematic reviews and meta-analyses. This methodology forms clinical thinking in parallel with the development of research and analytical competencies, which is one of the urgent tasks of modern medical education. The article reflects the experience of the Department of Internal Diseases of the Sechenov University in implementing a practice-oriented research module aimed at developing critical thinking using evidence-based medicine methods among students and residents. The inclusion of research competencies in the educational process will make it possible to qualitatively transform medical education and form a generation of competitive competent specialists in demand in the world of constantly developing technologies.

2 May 2024 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
CPChavdar Pavlov
Chavdar Pavlov
DTDaria Teplyuk
Daria Teplyuk
LLLeonid Lazebnik
Leonid Lazebnik
AAAleksandr Ametov
Aleksandr Ametov
EPEvgeniia Pashkova
Evgeniia Pashkova
AMAleksandr Maslakov
Aleksandr Maslakov
In September 2023, the European Association for the Study of the Liver (EASL) updated the disease nomenclature for non-alcoholic (metabolically associated) fatty liver disease. The goals of the revision were to increase awareness among health care professionals, civil society and patients about the disease, its course, treatment and outcomes; combating stigma; focusing on the initial etiological factor, including the main (cardiometabolic) risk of disease progression; improved diagnosis based on disease biomarkers; positive impact on the potency to search for new drugs; the ability to provide personalized medical care. The terms “non-alcoholic” and “fatty” were considered stigmatizing, and therefore, it was proposed to use the term steatotic liver disease (SLD) as the name of this nosology. The terms non-alcoholic fatty liver disease (NAFLD) or metabolic associated fatty liver disease (MAFLD) have been replaced by the term metabolic dysfunction-associated steatotic liver disease (MASLD). In the case of being combined with an alcohol factor, a diagnosis in which metabolic dysfunction is combined with alcoholic liver disease is referred to as MetALD. The fundamental principle in the diagnosis of MASLD is the presence of at least one of the cardiometabolic risk factors. Alcohol consumption interacts with cardiometabolic risk factors and increases the risk of SLD decompensation. The term nonalcoholic steatohepatitis (NASH), according to the new nomenclature, has been replaced by the term metabolic dysfunction-associated steatohepatitis (MASH). The adoption of the new nomenclature should help to increase awareness about the disease, its course and outcomes, as well as improve the quality of diagnosis and treatment.

19 November 2021 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
DTD. A. Teplyuk
D. A. Teplyuk
MSM. Ch. Semenistaya
M. Ch. Semenistaya
SSS. M. Sorokoletov
S. M. Sorokoletov
LLL. B. Lazebnik
L. B. Lazebnik
CPChavdar Pavlov
Chavdar Pavlov
Nonalcoholic fatty liver disease (NAFLD) is a disease which etiology is related to various metabolic, ethnic, genetic and even ecologic factors. Complexity of etiology and multiply pathogenesis ways, leading eventually to the lipid droplets appearance in hepatocytes, infl ammation process and parenchyma fi brosis in liver, and also frequent cardiometabolic comorbidities, together make diffi cult risks stratifi cation and prognosis evaluation in NAFLD patients. Another matter is a question of NAFLD therapy, since unifi ed pharmacotherapy approaches are not yet adopted worldwide, and lifestyle modifi cation being accepted as an eff ective therapeutic approach, is not followed by patients in real world setting. Current review is dedicated to the consideration of NAFLD diagnostics, its risk of progression and existing therapeutical capabilities.

10 December 2024 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
DTD. A. Teplyuk
D. A. Teplyuk
OLO. N. Levina
O. N. Levina
CPCh. S. Pavlov
Ch. S. Pavlov
SSS. M. Sorokoletov
S. M. Sorokoletov
EPE. Yu. Pashkova
E. Yu. Pashkova
ESE. V. Shutov
E. V. Shutov
Nonalcoholic fatty liver disease (NAFLD) is most commonly a component of the metabolic syndrome with a global prevalence of 25% and the number of patients continues to increase. According to current projections, in the near future, NAFLD will become the most common indication for liver transplantation. The search for new risk factors for the development and progression of this disease is actively underway. The article considers the role of intestinal microbiota in proinflammatory processes, bile acid metabolism and liver lipogenesis. Attention is paid to the qualitative composition of the microbiome depending on the stage of NAFLD. Conclusions are made about heterogeneity of the research results in case of NAFLD and relatively stable microbiota in liver cirrhosis. Faecalibacterium prausnitzii and its role in the progression of NAFLD are considered separately. Probable reasons for the disagreement of the results of the studies are presented. In the part devoted to the treatment of NAFLD, the focus is on the ways of correction of intestinal dysbiosis, the influence of various microbiological preparations on lipogenesis and the process of inflammation in the liver. The optimal composition of probiotic preparations is discussed in detail. Their combination with prebiotics and isolated administration of inulin, fructooligosaccharide. Conclusions are drawn that in the future the assessment of intestinal microbiome will help to improve therapeutic approaches in the treatment of NAFLD patients.

3 October 2025 in Russian Journal of Evidence-Based Gastroenterology
Verified
Journal Article
Closed access
CPChavdar Pavlov
Chavdar Pavlov
TTT.A. Turankova
T.A. Turankova
DTD.A. Teplyuk
D.A. Teplyuk
AMA.V. Mudrova
A.V. Mudrova
YUYu.P. Uspenskiy
Yu.P. Uspenskiy
APArtem Poromov
Artem Poromov
The global prevalence of chronic liver diseases (CLD) is steadily increasing, with the most common etiologies being metabolic disorders and alcohol misuse. Despite the effectiveness of non-pharmacological interventions, their impact is often insufficient. Objective. To conduct a clinical and epidemiological analysis of common forms of CLD —nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), and drug-induced liver injury (DILI) — in outpatient practice, and to assess the use of hepatotropic agents, including combination therapy with glycyrrhizic acid and phospholipids (GA+PL). Material and methods. The multicenter PROMETHEUS study comprised two stages: a retrospective analysis of 9.149 medical records and a prospective non-interventional observation of 574 patients treated with GA+PL (Phosphogliv). Changes in biochemical liver function parameters, treatment tolerability, and adverse event rates were evaluated. Results. NAFLD accounted for 72.8% of cases, ALD for 20.1%, and DILI for 7.1%. Comorbidities were present in 90% of patients, and non-pharmacological interventions were prescribed in 95.1%. Monotherapy with hepatotropic agents was associated with reductions in ALT and AST levels (ΔALT 17.28±17.46 U/L; ΔAST 15.04±15.45 U/L). Combination therapy with GA+PL achieved normalization of ALT, AST, and ALP in patients with initially elevated enzyme levels within comparable time frames (p<0.05). At the end of GA+PL therapy, AST normalized in 69% of patients and ALT in 45%. A stepwise regimen (parenteral followed by oral administration) resulted in ALT normalization in 53.5% of patients after a 3-week course. Subjective improvement was reported by over 99% of patients, while the incidence of adverse events was 0.03%. Conclusions. In outpatient practice, NAFLD predominates among CLD cases. Monotherapy with hepatotropic agents reduces liver enzyme activity, while combination therapy with GA+PL yields greater improvements in clinical and biochemical parameters. A stepwise regimen shortens treatment duration without compromising efficacy.

20 September 2024 in Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
ESE. V. Shutov
E. V. Shutov
SBS. A. Bolshakov
S. A. Bolshakov
TMT. A. Makarova
T. A. Makarova
IFI. A. Fedoseeva
I. A. Fedoseeva
DTD. A. Teplyuk
D. A. Teplyuk
SSS. M. Sorokoletov
S. M. Sorokoletov
Recent technological advances have significantly enhanced our understanding of the role microbial communities play in the human body. The gut microbiota, one of the most diverse microbiomes, consists of over 35,000 bacterial species and 10 million genes, leading researchers to consider it as an additional organ. This whiles relatively stable within each individual highly influenced by exogenous and endogenous factors. Collectively, the gut microbiota functions as a "second genome", profoundly impacting the host’s metabolic pathways and regulating the body’s complex homeostatic balance.Research into the "microbe–host" interaction, both in health and disease, has garnered worldwide scientific. In chronic kidney disease (CKD), the gut microbiota undergoes significant changes, and growing evidences suggests that dysbiosis plays a crucial role in the progression of renal failure. Key pathological process, such as the production of gut-derived uremic toxins, decreased synthesis of short– chain fatty acids, altered intestinal pH, compromised intestinal barrier function, and heightened systemic inflammation, are all linked the intestinal microbiota. However, relationship between these changes and the pathogenesis and progression of kidney disease requires further investigation. Advances in microbiome research, including metagenomic and metatranscriptomic analyses, alongside proteomic, metabolomics, and immunomic studies, have greatly expanded our understanding of microbiomal community structure and functions. These technologies, coupled with mechanistic experiments in model systems, have deepened our knowledge of how the microbiome influences metabolism. Current research aims to explore the bidirectional relationship between the microbiota and the host, identifying potential interventions that could help restore a mutualistic relationship.